WHO ICTRP trial
Feasibility of aggressively lowering urine albumin in individuals with kidney…
EUCTR2021-001661-21-DK · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2021-001661-21-DK |
|---|---|
| Public title | Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - A Pilot Study |
| Scientific title | Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study |
| Primary sponsor | Herlev and Gentofte Hospital |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Denmark |
| Conditions | Diabetic Kidney Disease MedDRA version: 21.1 Level: LLT Classification code 10012687 Term: Diabetic renal disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] |
| Interventions | Trade Name: Forxiga Pharmaceutical Form: Tablet INN or Proposed INN: Dapagliflozin CAS Number: 461432-26-8 Other descriptive name: DAPAGLIFLOZIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- INN or… |
| Registration date | May 17, 2021 |
| Target size | 20 |
| Secondary IDs | WP3.protocol.v7;PRIMETIME - WP3 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: